292 related articles for article (PubMed ID: 32814538)
21. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery.
Chaudhry A; Roels C; Lee J
Can J Diabetes; 2022 Dec; 46(8):843-850. PubMed ID: 36068154
[TBL] [Abstract][Full Text] [Related]
22. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
[TBL] [Abstract][Full Text] [Related]
23. Sodium-Glucose Cotransporter-2 Inhibitor-Related Diabetic Ketoacidosis: Accuracy Verification of Operational Definition.
Kang DY; Kim H; Ko S; Kim H; Shinn J; Kang MG; Byeon SJ; Choi JH; Shin SY; Kim HS
J Korean Med Sci; 2022 Feb; 37(7):e53. PubMed ID: 35191230
[TBL] [Abstract][Full Text] [Related]
24. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
Menghoum N; Oriot P; Hermans MP; Mariage JL
Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
[TBL] [Abstract][Full Text] [Related]
26. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
27. The risk factors of diabetic ketosis and diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors: a retrospective study.
Zhao Q; Tan Y; Wu Q; Xiao X; Wei X; Nian M; Yao J; Fan N; Wang R; Fan G
Expert Opin Drug Saf; 2024 Jan; 23(1):57-65. PubMed ID: 37947121
[TBL] [Abstract][Full Text] [Related]
28. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
[TBL] [Abstract][Full Text] [Related]
29. The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study.
Werkman NCC; Driessen JHM; Stehouwer CDA; Vestergaard P; Schaper NC; van den Bergh JP; Nielen JTH
Cardiovasc Diabetol; 2023 Jun; 22(1):160. PubMed ID: 37386427
[TBL] [Abstract][Full Text] [Related]
30. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
[TBL] [Abstract][Full Text] [Related]
31. Sodium-glucose cotransport-2 inhibitor induced ketoacidosis following coronary artery bypass surgery: implications for management.
McCann M; O'Brien A; Larbalestier R; Davis T
Intern Med J; 2022 May; 52(5):876-879. PubMed ID: 35538006
[TBL] [Abstract][Full Text] [Related]
32. A retrospective analysis of the incidence, outcome and factors associated with the occurrence of euglycemic ketoacidosis in diabetic patients on sodium glucose co-transporter - 2 inhibitors undergoing cardiac surgery.
Murugesan KB; Balakrishnan S; Arul A; Ramalingam S; Srinivasan M
Ann Card Anaesth; 2022; 25(4):460-465. PubMed ID: 36254911
[TBL] [Abstract][Full Text] [Related]
33. Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team.
Champion M; Wills Avila G; Garcia AE; Álvarez Delgado FM; Valdez CA
J Prim Care Community Health; 2024; 15():21501319241231398. PubMed ID: 38353180
[TBL] [Abstract][Full Text] [Related]
34. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
Yen FS; Hwu CM; Liu JS; Wu YL; Chong K; Hsu CC
Ann Intern Med; 2024 Jun; 177(6):693-700. PubMed ID: 38684099
[TBL] [Abstract][Full Text] [Related]
35. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes.
Al-Ozairi E; Irshad M; Taghadom E; Sojan L; Al Kandari J; Alroudhan D; le Roux CW
Obesity (Silver Spring); 2023 Mar; 31(3):716-723. PubMed ID: 36811241
[TBL] [Abstract][Full Text] [Related]
37. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of SGLT2 inhibitors in individuals with type 1 diabetes under continuous subcutaneous insulin infusion: a real-world study.
Silva VB; Fonseca L; Duarte DB; Puga FM; Assuncao G; Garrido S; Teixeira S; Vilaverde J; Cardoso MH
Endocr Regul; 2023 Jan; 57(1):144-151. PubMed ID: 37561831
[No Abstract] [Full Text] [Related]
39. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Ueda P; Svanström H; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
BMJ; 2018 Nov; 363():k4365. PubMed ID: 30429124
[TBL] [Abstract][Full Text] [Related]
40. Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.
Rao L; Ren C; Luo S; Huang C; Li X
Acta Diabetol; 2021 Jul; 58(7):869-880. PubMed ID: 33651228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
